# RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC

> **NCT02426450** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 28 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** RFA
- **DRUG:** Oxaliplatin
- **DRUG:** 5-Fluorouracil/Leucovorin

## Key facts

- **NCT ID:** NCT02426450
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-04
- **Primary completion:** 2015-10
- **Final completion:** 2017-04
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2015-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02426450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02426450, "RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02426450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*